LEGENDS FOR SUPPLEMENTARY TABLES AND FIGURES

**Supplementary Table S1.** Biodistribution of $^{111}$In-CHX-A”-DTPA-CS-1008 in BALB/c nu/nu CT26 tumor-bearing mice.

**Supplementary Table S2.** Biodistribution of $^{111}$In-CHX-A”-DTPA-CS-1008 in BALB/c nu/nu WiDr tumor-bearing mice

**Supplementary Figure S1** Planar gamma camera imaging with $^{111}$In-CHX-A"-DTPA-CS-1008 in mice bearing CT26 tumors (A, B) or COLO 205 tumors (C, D) at seven days post injection. Arrows indicate the location of the tumors.

**Supplementary Figure S2.** TUNEL assay for apoptosis. A, TACS-Nuclease treated positive control of a COLO 205 tumor section; B, unlabeled experimental negative control; C, a characteristic area for COLO 205 tumors treated with 0.2 mg/kg CS-1008; D, a characteristic area for COLO 205 tumors treated with 10 mg/kg CS-1008. Magnification: × 200.

**Supplementary Figure S3.** *In vivo* saturation of $^{111}$In-CHX-A”-DTPA-CS-1008 in WiDr tumors demonstrated by planar gamma camera imaging (A, 0.2 mg/kg; B, 0.5 mg/kg and C, 10 mg/kg). Representative whole body images (*left*), surface-rendered CT (*middle*) and fused images (*right*) are shown. Dorsal 20-minute images were collected.